Evidence map›Paper›PMID 33185015›Full record

ArticleNeurogastroenterology and motility2021

Prokinetic actions of luminally acting 5-HT

John R Konen, Melody M Haag, Daria Guseva, Molly Hurd, Alisha A Linton, Brigitte Lavoie, Colleen B Kerrigan, Emily Joyce, Stephan C Bischoff, Steve Swann and 7 more

Open access · greenAbstract read
In one paragraph

Article in Neurogastroenterology and motility, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. International journal of molecular sciences · 2025
    Article
  3. Enteric nervous system as a therapeutic target in gastrointestinal disorders.World journal of gastrointestinal pharmacology and therapeutics · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Protective actions of a luminally acting 5-HTNeurogastroenterology and motility · 2023
    Article
  8. Tryptophan-synthesizing bacteria enhance colonic motility.Neurogastroenterology and motility · 2023
    Article
  9. Review
  10. Review
  11. Review
  12. Understanding the Molecular Basis of 5-HTInternational journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 3 countries.

John R KonenDepartment of Neurological Sciences, University of Vermont, Burlington, VT, USA.
Melody M HaagDepartment of Neurological Sciences, University of Vermont, Burlington, VT, USA.
Daria GusevaDepartment of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany.
Molly HurdDepartment of Neurological Sciences, University of Vermont, Burlington, VT, USA.
Alisha A LintonDepartment of Neurological Sciences, University of Vermont, Burlington, VT, USA.
Brigitte LavoieDepartment of Neurological Sciences, University of Vermont, Burlington, VT, USA.
Colleen B KerriganDepartment of Neurological Sciences, University of Vermont, Burlington, VT, USA.
Emily JoyceDepartment of Neurological Sciences, University of Vermont, Burlington, VT, USA.
Stephan C BischoffDepartment of Nutritional Medicine, University of Hohenheim, Stuttgart, Germany.
Steve SwannTakeda Pharmaceutical Company, San Diego, CA, USA.
Luana GriffinTakeda Pharmaceutical Company, San Diego, CA, USA.
Jun MatsukawaTakeda Pharmaceutical Company, San Diego, CA, USA.
Matthew D FalkTakeda Pharmaceutical Company, San Diego, CA, USA.
Tony S GibsonTakeda Pharmaceutical Company, San Diego, CA, USA.
Grant W HennigDepartment of Pharmacology, University of Vermont, Burlington, VT, USA.
Jill WykoskyTakeda Pharmaceutical Company, San Diego, CA, USA.
Gary M MaweDepartment of Neurological Sciences, University of Vermont, Burlington, VT, USA.ORCID 0000-0001-8876-8468
University of Vermont · USTakeda (United States) · USUniversity of Hohenheim · DE

Funding

Autoimmune mechanisms of gastrointestinal dysmotility in multiple sclerosisR01DK113800 · NIDDK · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI MAWE, GARY M · 2017 to 2020
$1.8M
NIDDK NIH HHS R01 DK113800
6 · The paper itself

Abstract

background5-HT

methodsNon-absorbed 5-HT KEY

resultsPharmacological screening demonstrated selectivity and potency of test agonists for 5-HT CONCLUSIONS AND INFERENCES: These findings demonstrated that stimulation of epithelial 5-HT

Indexed as

AnimalsCHO CellsColonConstipationCricetinaeCricetulusGastrointestinal MotilityHumansIntestinal MucosaMaleMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicReceptors, Serotonin, 5-HT4Serotonin 5-HT4 Receptor AgonistsReceptors, Serotonin, 5-HT4Serotonin 5-HT4 Receptor Agonists5-HT4 receptorconstipationepithelial targetperistalsisprokineticserotonin

Identifiers

PMID33185015
PMCPMC7990683
OpenAlexW3102999725

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.